ABION Inc. (KOSDAQ:203400)

Market Cap	145.19B
Revenue (ttm)	995.57M
Net Income (ttm)	-46.51B
Shares Out	28.64M
EPS (ttm)	-1,805.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	116,841
Average Volume	232,330
Open	5,600.00
Previous Close	5,600.00
Day's Range	5,250.00 - 5,640.00
52-Week Range	5,240.00 - 13,000.00
Beta	1.01
RSI	30.88
Earnings Date	May 15, 2025

About ABION

ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various re...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 203400

Financial Performance

In 2024, ABION's revenue was 759.68 million, a decrease of -40.38% compared to the previous year's 1.27 billion. Losses were -43.38 billion, 48.5% more than in 2023.